Rexha Pharmaceuticals Private Limited
Founded in 2022 and headquartered in Maharashtra, India.
2022 | Pune, Maharashtra (India) | Active
Rexha Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 2 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
About Rexha Pharmaceuticals
Rexha Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 March 2022 (Two years and 11 months 27 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Yasmin Banna, Taheruzzaman Khan, Nawab Niyazi, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290PN2022PTC209097
- Company No.
209097
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Chemicals
Who are the key members and board of directors at Rexha Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yasmin Banna  | Director | 01-Mar-2023 | Current |
| Taheruzzaman Khan | Director | 04-Mar-2022 | Current |
| Nawab Niyazi | Director | 04-Mar-2022 | Current |
| Haris Khan | Director | 04-Mar-2022 | Current |
Financial Performance of Rexha Pharmaceuticals.
Enhance accessibility to Rexha Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rexha Pharmaceuticals?
Unlock access to Rexha Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rexha Pharmaceuticals?
Rexha Pharmaceuticals has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rexha Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rexha Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.